The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?
Open accessAbstract
BACKGROUND: Evaluation of response to treatment is a key aspect in cancer therapy. Response Evaluation Criteria in Solid Tumors (RECIST) are used in most oncology trials, but those criteria evaluate only unidimensional tumor measurements and disregard the extent of necrosis, which is the target of all effective locoregional therapies. Therefore, the European Association for the Study of the Liver (EASL) guidelines recommended that assessment of tumor response should incorporate the reduction in viable tumor burden. The current report provides an assessment of the agreement/concordance between both RECIST and the EASL guidelines for the evaluation of response to therapy. METHODS: The authors evaluated a cohort of 55 patients within prospective studies, including 24 patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) with drug eluting beads (DEB‐TACE) and 31 patients who underwent percutaneous ablation (percutaneous ethanol injection [PEI]/radiofrequency [RF]). Triphasic helical computed tomography scans were performed at baseline, at 1 month, and at 3 months after procedure, and 2 independent radiologists evaluated tumor response. RESULTS: Evaluating response according to RECIST criteria, no patients achieved a complete response (CR), 21.8% of patients achieved a partial response (PR) (none in the PEI/RF group), 47.3% of patients had stable disease (SD), and 30.9% of patients had progressive disease (PD). When response was evaluated according to the EASL guidelines, 54.5% of patients achieved a CR, 27.3% of patients achieved a PR, 3.6% of patients had SD, and 14.5% had PD. The κ coefficient was 0.193 (95% confidence interval, 0.0893‐0.2967; P < .0001). CONCLUSIONS: RECIST missed all CRs and underestimated the extent of partial tumor response because of tissue necrosis, wrongly assessing the therapeutic efficacy of locoregional therapies. This evaluation should incorporate the reduction in viable tumor burden as recognized by nonenhanced areas on dynamic imaging studies. Cancer, 2009. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationTemsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Self-citationLlovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Self-citationLo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Self-citationLencioni, R. A., Allgaier, H.-P., Cioni, D., Olschewski, M., Deibert, P., Crocetti, L., Frings, H., Laubenberger, J., Zuber, I., Blum, H. E., et al. (2003) · Radiology · doi:10.1148/radiol.2281020718 · Cited by 998
Varela, M., Real, M. I., Burrel, M., Forner, A., Sala, M., Brunet, M., Ayuso, C., Castells, L., Montañá, X., Llovet, J. M., et al. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.10.020 · Cited by 941
Self-citationShiina, S., Teratani, T., Obi, S., Sato, S., Tateishi, R., Fujishima, T., Ishikawa, T., Koike, Y., Yoshida, H., Kawabe, T., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.009 · Cited by 877
Lencioni, R., Cioni, D., Crocetti, L., Franchini, C., Pina, C. D., Lera, J., & Bartolozzi, C. (2005) · Radiology · doi:10.1148/radiol.2343040350 · Cited by 867
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
Byrne, M. J., & Nowak, A. K. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh059 · Cited by 645
Lin, S.-M., Lin, C.-J., Lin, C.-C., Hsu, C.-W., & Chen, Y.-C. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.003 · Cited by 609
Choi, H., Charnsangavej, C., Faria, S. D. C., Tamm, E. P., Benjamin, R. S., Johnson, M. M., Macapinlac, H. A., & Podoloff, D. A. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.183.6.01831619 · Cited by 459
Sala, M., Llovet, J. M., Vilana, R., Bianchi, L., Solé, M., Ayuso, C., Brú, C., & Bruix, J. (2004) · Hepatology · doi:10.1002/hep.20465 · Cited by 447
Self-citationRECIST revisited: A review of validation studies on tumour assessment
Therasse, P., Eisenhauer, E. A., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.026 · Cited by 422
Sato, K., Lewandowski, R. J., Bui, J. T., Omary, R., Hunter, R. D., Kulik, L., Mulcahy, M., Liu, D., Chrisman, H., Resnick, S., et al. (2006) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-005-0171-4 · Cited by 237
Measuring response in a post-RECIST world: from black and white to shades of grey
Michaelis, L. C., & Ratain, M. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1883 · Cited by 192
Drug development in oncology: classical cytotoxics and molecularly targeted agents
Kummar, S., Gutierrez, M., Doroshow, J. H., & Murgo, A. J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02713.x · Cited by 177
Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards
Scher, H. I., Morris, M. J., Kelly, W. K., Schwartz, L. H., & Heller, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0109 · Cited by 130
van Klaveren, R. V., Aerts, J., de Bruin, H. D., Giaccone, G., Manegold, C., & van Meerbeeck, J. V. (2004) · Lung Cancer · doi:10.1016/s0169-5002(03)00292-7 · Cited by 126
Imaging of Hepatocellular Carcinoma After Treatment with Yttrium-90 Microspheres
Keppke, A. L., Salem, R., Reddy, D. H., et al. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.0706 · Cited by 123
Cammà, C., Marco, V. D., Orlando, A., Sandonato, L., Casaril, A., PARISI, P., Alizzi, S., Sciarrino, E., Virdone, R., Pardo, S., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.042 · Cited by 120
Choi, H. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0055-4 · Cited by 100
Watanabe, H., Yamamoto, S., Kunitoh, H., Sekine, I., Yamamoto, N., Ohe, Y., Tamura, T., Kodama, T., Sugimura, K., & Saijo, N. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01394.x · Cited by 69
Historical and methodological developments in clinical trials at the national cancer institute
Gehan, E. A., & Schneiderman, M. A. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090803 · Cited by 62
Therasse, P., Cesne, A. L., Glabbeke, M. M. V., Verweij, J., & Judson, I. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.005 · Cited by 58
Barnacle, A., & McHugh, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20344 · Cited by 40
CT, RECIST, and malignant pleural mesothelioma
Nowak, A. K. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.03.030 · Cited by 35
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
Self-citationFrom RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update
Ahmed, M., Solbiati, L., Brace, C. L., Breen, D. J., Callstrom, M. R., Charboneau, J. W., Chen, M.-H., Choi, B. I., de Baère, T., Dodd, G. D., et al. (2014) · Radiology · doi:10.1148/radiol.14132958 · Cited by 1,346
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Metadata
- Authors
- Forner, A., Ayuso, C., Varela, M., Rimola, J., Hessheimer, A. J., de Lope, C. R., Reig, M., Bianchi, L., Llovet, J. M., & Bruix, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-01-20
- Volume
- 115
- Issue
- 3
- Pages
- 616-623
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2024029636
- Cited by
- 426
- References
- 34
- FWCI
- 16.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.